Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,808

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Open access
Wan, Paul T.C, Garnett, Mathew J, Roe, S.Mark, Lee, Sharlene, Niculescu-Duvaz, Dan, Good, Valerie M, Project, Cancer Genome, Jones, C.Michael, Marshall, Christopher J, Springer, Caroline J, Barford, David, Marais, Richard·2004·Cell
DOI 10.1016/s0092-8674(04)00215-6
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0092-8674(04)00215-6

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Mutations of the BRAF gene in human cancer

    Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

    Self-citation

  • RAS oncogenes: the first 30 years

    Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 2×

    “Approximately 15% of human cancers have activating RAS mutationsSummary (Malumbres and Barbacid, 2003), and recently mutations in B-RAF were identified in a large-scale screenOver 30 mutations of the B-RAF gene associated with for genes mutated in human cancer (Davies et al., 2002).human cancers…”
    Background

  • RAF/RAS oncogenes and mismatch-repair status

    Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×

    “Here of malignant melanomas and occur with moderate towe show that of 22 B-RAF mutants analyzed, 18 have high frequency in colorectal (Rajagopalan et al., 2002),elevated kinase activity and signal to ERK in vivo.”
    Background

Show all 3 references

Research works printed but not linked: 43

  1. Avruch, 2001, Ras activation of the Raf kinase, Recent Prog. Horm. Res., 56, 127, 10.1210/rp.56.1.127 · DOI · Paper page
  2. Azam, 2003, Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL, Cell, 112, 831, 10.1016/S0092-8674(03)00190-9 · DOI · Paper page
  3. Bankston, 2002, A scaleable Synthesis of BAY 43–9006, Organic Process Res. & Dev., 6, 777, 10.1021/op020205n · DOI
  4. Blagosklonny, 2002, Hsp-90-associated oncoproteins, Leukemia, 16, 455, 10.1038/sj.leu.2402415 · DOI · Paper page
  5. Brose, 2002, BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res., 62, 6997
  6. Brunger, 1998, Crystallography & NMR system, Acta Crystallogr. D Biol. Crystallogr., 54, 905, 10.1107/S0907444998003254 · DOI · Paper page
  7. CCP4, 1991, The CCP4 (Collaborative Computational Project Number 4) Suite, Acta Cryst D, 50, 760
  8. Chong, 2001, Positive and negative regulation of Raf kinase activity and function by phosphorylation, EMBO J., 20, 3716, 10.1093/emboj/20.14.3716 · DOI · Paper page
  9. Cohen, 2003, Lack of BRAF mutation in primary uveal melanoma, Invest. Ophthalmol. Vis. Sci., 44, 2876, 10.1167/iovs.02-1329 · DOI
  10. Dent, 1989, A whole-mount immunocytochemical analysis of the expression of the intermediate filament protein vimentin in Xenopus, Development, 105, 61, 10.1242/dev.105.1.61 · DOI · Paper page
  11. Fabian, 1993, Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase, Mol. Cell. Biol., 13, 7170, 10.1128/MCB.13.11.7170 · DOI · Paper page
  12. Farrar, 1996, Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization, Nature., 383, 178, 10.1038/383178a0 · DOI · Paper page
  13. Glover, 1995, Election of activating mutations of c-fms in FDC-P1 cells, Oncogene, 11, 1347
  14. Grant, 1998, Kinetic analyses of mutations in the glycine-rich loop of cAMP-dependent protein kinase, Biochemistry, 37, 7708, 10.1021/bi972987w · DOI
  15. Hubbard, 1994, Crystal structure of the tyrosine kinase domain of the human insulin receptor, Nature, 372, 746, 10.1038/372746a0 · DOI · Paper page
  16. Ikenoue, 2003, Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors, Cancer Res., 63, 8132
  17. Johnson, 1996, Active and inactive protein kinases, Cell, 85, 149, 10.1016/S0092-8674(00)81092-2 · DOI · Paper page
  18. Jones, 1991, Improved methods for building protein models in electron density maps and the location of errors in these models, Acta Crystallogr. A, 47, 110, 10.1107/S0108767390010224 · DOI · Paper page
  19. Jones, 1996, Bone morphogenetic protein-4 (BMP-4) acts during gastrula stages to cause ventralization of Xenopus embryos, Development, 122, 1545, 10.1242/dev.122.5.1545 · DOI
  20. Kitayama, 1995, Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines, Blood, 85, 790, 10.1182/blood.V85.3.790.bloodjournal853790 · DOI · Paper page
  21. Kolch, 2000, Meaningful relationships, Biochem. J., 351, 289, 10.1042/0264-6021:3510289 · doi:10.1042/0264-6021:3510289 · Paper page
  22. Lowinger, 2002, Design and discovery of small molecules targeting raf-1 kinase, Curr. Pharm. Des., 8, 2269, 10.2174/1381612023393125 · DOI
  23. Luo, 1996, Oligomerization activates c-Raf-1 through a Ras-dependent mechanism, Nature, 383, 181, 10.1038/383181a0 · DOI · Paper page
  24. Lyons, 2001, Discovery of a novel Raf kinase inhibitor, Endocr. Relat. Cancer, 8, 219, 10.1677/erc.0.0080219 · DOI · Paper page
  25. MacNicol, 2000, Disruption of the 14–3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation, J. Biol. Chem., 275, 3803, 10.1074/jbc.275.6.3803 · DOI
  26. Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762 · DOI · Paper page
  27. Marais, 1997, Differential regulation of Raf-1, A-Raf and B-Raf by oncogenic Ras and tyrosine kinases, J. Biol. Chem., 272, 4378, 10.1074/jbc.272.7.4378 · DOI · Paper page
  28. Marais, 1998, Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C, Science, 280, 109, 10.1126/science.280.5360.109 · DOI · Paper page
  29. Mason, 1999, Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation, EMBO J., 18, 2137, 10.1093/emboj/18.8.2137 · DOI · Paper page
  30. Michaud, 1995, 14–3-3 is not essential for Raf-1 function, Mol. Cell. Biol., 15, 3390, 10.1128/MCB.15.6.3390 · DOI · Paper page
  31. Morrison, 2001, Ksr, J. Cell Sci., 114, 1609, 10.1242/jcs.114.9.1609 · DOI · Paper page
  32. Morrison, 1997, The complexity of Raf-1 regulation, Curr. Opin. Cell Biol., 9, 174, 10.1016/S0955-0674(97)80060-9 · DOI · Paper page
  33. Nagar, 2002, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571), Cancer Res., 62, 4236
  34. Pargellis, 2002, Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site, Nat. Struct. Biol., 9, 268, 10.1038/nsb770 · DOI · Paper page
  35. Rapp, 1983, Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus, Proc. Natl. Acad. Sci. USA, 80, 4218, 10.1073/pnas.80.14.4218 · DOI · Paper page
  36. Robinson, 1997, Mitogen-activated protein kinase pathways, Curr. Opin. Cell Biol., 9, 180, 10.1016/S0955-0674(97)80061-0 · DOI · Paper page
  37. Schindler, 2000, Structural mechanism for STI-571 inhibition of abelson tyrosine kinase, Science, 289, 1938, 10.1126/science.289.5486.1938 · DOI · Paper page
  38. Singer, 2003, Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma, J. Natl. Cancer Inst., 95, 484, 10.1093/jnci/95.6.484 · DOI · Paper page
  39. Stancato, 1993, Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system, J. Biol. Chem., 268, 21711, 10.1016/S0021-9258(20)80600-0 · DOI · Paper page
  40. Weber, 2001, Active Ras induces heterodimerization of cRaf and BRaf, Cancer Res., 61, 3595
  41. Yang, 2002, Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP, Nat. Struct. Biol., 9, 940, 10.1038/nsb870 · DOI · Paper page
  42. Yuen, 2002, Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia, Cancer Res., 62, 6451
  43. Zhang, 2000, Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601, EMBO J., 19, 5429, 10.1093/emboj/19.20.5429 · DOI · Paper page

Cited by

See all 2,808

Metadata

Authors
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., Barford, D., & Marais, R.
Venue
Cell
Publisher
Elsevier BV
Published
2004-03
Volume
116
Issue
6
Pages
855-867
ISSN
0092-8674 (ISSN-L)
DOI
10.1016/s0092-8674(04)00215-6
OpenAlex
W2124662474
Cited by
2,808
References
3
FWCI
33.24
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. https://app.cochat.ai/papers/10.1016/s0092-8674(04)00215-6
The paper
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., Barford, D., & Marais, R. (2004). Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell. https://doi.org/10.1016/s0092-8674(04)00215-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.